Skip main navigation
Close Drawer MenuOpen Drawer Menu
APA Publishing Logo

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Site maintenance Monday, July 8th, 2024. Please note that access to some content and account information will be unavailable on this date.
Back to table of contents
Clinical and Research NewsFull Access

NEJM Journal Watch Psychiatry Recognizes AJP for Top Psychiatry Stories of 2018

Published Online:15 Jan 2019https://doi.org/10.1176/appi.pn.2019.1b51

In addition to being recognized as a top article by AJP editors (Psychiatric News, January 15, 2019), the study by Alain Brunet, Ph.D., and colleagues revealing the benefit of the beta-blocker propranolol for patients with PTSD was selected by NEJM Journal Watch Psychiatry as one of the top psychiatry stories of 2018.

“Propranolol presumably acts by altering the amount of emotional fear associated with the reconsolidation of activated memory traces,” Joel Yager, M.D., associate editor of NEJM Journal Watch Psychiatry wrote in comments reflecting on the study. “The simplicity of the intervention is noteworthy, but currently its routine employment would be premature,” he added. Yager is a professor of psychiatry at the University of Colorado.

The NEJM Journal Watch Psychiatry editorial board also recognized APA’s Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (AUD), released in January 2018. The editors acknowledged APA’s efforts at educating physicians about the benefits and risks of approved AUD medications, which are simple to provide yet greatly underutilized. ■

“NEJM Journal Watch Psychiatry Top Stories of 2018” can be accessed here. “The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder” is available here.